ArticleThe Journal of pharmacology and experimental therapeutics2014

Clinically relevant doses of candesartan inhibit growth of prostate tumor xenografts in vivo through modulation of tumor angiogenesis.

Ahmed Alhusban et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.